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bstract
We have evaluated an oral vaccine based on an Salmonella enteric serovar typhi (S. typhi) Ty2 derivative TSB7 harboring deletion muta-
ions in ssaV (SPI-2) and aroC together with a chromosomally integrated copy of eltB encoding the B subunit of enterotoxigenic Escherichia
oli heat labile toxin (LT-B) in volunteers. Two oral doses of 108 or 109 CFU were administered to two groups of volunteers and both
oses were well tolerated, with no vaccinemia, and only transient stool shedding. Immune responses to LT-B and S. typhi lipopolysaccha-
ide were demonstrated in 67 and 97% of subjects, respectively, without evidence of anti-carrier immunity preventing boosting of LT-B
esponses in many cases. Further development of this salmonella-based (spi-VEC) system for oral delivery of heterologous antigens appears
arranted.
2007 Elsevier Ltd.
oli
d
E
t
c
[
s
c
Open access under CC BY license.eywords: Typhoid; Salmonella; Oral vaccine; ETEC; Enterotoxigenic E. c
. Introduction
Enterotoxigenic Escherichia coli (ETEC), a significant
ause of travelers’ diarrhea, is usually transmitted by the
onsumption of contaminated food and water arising from
oor hygiene and sanitation. ETEC infection is endemic
n the developing world and is also a major public health
roblem in children in these countries, causing an estimated
10 million cases of diarrhea and leading to approximately
80,000 deaths worldwide each year. Due to the debilitat-
ng effects of ETEC infections, considerable effort has been
∗ Corresponding author at: Centre for Infection, St. George’s Vaccine Insti-
ute, London SW17 ORE, UK. Tel.: +44 20 8725 5826;
ax: +44 20 8725 3487.
E-mail address: d.lewis@sgul.ac.uk (D.J.M. Lewis).
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Open access under CC BY license.evoted to the development of a vaccine that will prevent
TEC diarrhea in humans.
Some of the strongest evidence supporting the supposi-
ion that an effective vaccine against ETEC can be developed
omes from a large field study carried out in Bangladesh
1,2] using an oral vaccine against cholera. The vaccine con-
isted of whole cell killed cholera plus CT-B—a subunit of
holera toxin which cross-reacts with the equivalent sub-
nit of the heat labile enterotoxin (LT-B) of ETEC. Two
oses of the vaccine conferred protection against ETEC diar-
hea in 73% of recipients for a period of 3 months. This
as an important finding, not only providing evidence thatmmunization could confer protection against ETEC, but
lso demonstrating that the CT-B component alone provides
rotective immunity against ETEC disease through immuno-
ogical cross-reactivity with LT-B.
4 cine 25
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It has already been demonstrated that several ETEC anti-
ens including LT-B can be expressed in live attenuated
almonella strains and immune responses can be elicited
n animal models [3–7]. Here, we report the ability of a S.
yphi-based oral vaccine, which may form the basis of a com-
ined typhoid-ETEC travelers’ diarrhea vaccine, to deliver an
TEC antigen to the humoral immune system in humans.
. Material and methods
.1. Study design
The study was open label, with sequential, dose-escalating
ohorts, and not placebo controlled. The study was con-
ucted under a Clinical Trial Exemption from the UK
edicines Control Agency, now known as The Medicine
ealthcare Products Regulatory Agency and permission
or Deliberate Release of a GMO was obtained from
epartment for the Environment Food and Rural Affairs
DEFRA). Primary ethical permission was obtained from
he Wandsworth Local Research Ethics Committee, and per-
ission to enroll students from Kingston University was
ranted by the Kingston University Local Research Ethics
ommittee. Written informed consent was obtained after
ubmission of a detailed explanation of the protocol. Sub-
ects were excluded if they had a sensitivity to ciprofloxacin,
rimethoprim-sulphamethoxazole or related antibiotics, had
known immunodeficiency or were on immunosuppressive
herapy, had a history of gallbladder or gastrointestinal dis-
ase or some other significant medical condition, had received
mmunization against Salmonella in the preceding 5 years, or
ad an anti-S. typhi O-antibody titer in serum as determined
y enzyme-linked immunosorbent assay (ELISA) that was
3 standard deviations above the mean of a group of healthy
ontrols. Subjects were also excluded if they had household
ontacts who were at risk for transmission of vaccine bacteria.
Vaccines were manufactured according to Good Man-
facturing Practice protocols by Eurogentec Ltd. (Liege,
elgium) and were derived from a tested and characterized
aster Cell Bank, also manufactured according to cGMP
rotocols. The vaccine was packed by dose (108 or 109 CFU).
ach dose of vaccine was frozen in a 1.5 ml cryo-vial. The
ials of the vaccine were stored at −80 ± 5 ◦C, until required
or administration. Prior to administration, each dose of
accine was be made up to 50 ml with 2% (w/v) sodium bicar-
onate solution no more than 30 min before dosing orally to
olunteers.
Thirty-six volunteers were recruited (age range, 18–50
ears). After fasting for at least 2 h, the volunteers swallowed
00 ml of 2% (w/v) sodium bicarbonate solution to buffer
astric acid and then received a single dose of either 108 or
09 CFU of ETEC Vaccine 1, on two occasions, 56 days apart
i.e. vaccine administered at the same dose level on two occa-
ions 56 days apart). Volunteers remained at the investigative
ite, under observation, for 48 h following each immunization
m
i
b
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pulse, blood pressure and respiratory rate were measured
rior to immunization and at 30, 60 and 120 min after immu-
ization) and then followed up daily for 1 week and weekly
or 1 month post-immunization. Volunteers were assessed for
eactogenicity and other adverse events by physical exami-
ation and by the completion of diary cards.
Subjects received the vaccine in three sequential groups
f 12 subjects (Groups 1, 2 and 3). Due to constraints on the
umber of subjects that could be accommodated at any one
ime at the site, each group was vaccinated in two cohorts of
ix subjects. Group 1 (comprising cohorts 1 and 2) received
dose of 108 CFU. The dose level in Group 2 (comprising
ohorts 3 and 4) depended on the safety profile observed at the
rst (108 CFU) dose. The dose level in Group 3 (comprising
f cohorts 5 and 6) depended on the safety profile of the
revious two groups. The intention was to dose escalate to
09 CFU in Group 2 and 3. Subjects were administered the
econd dose of the vaccine after a satisfactory evaluation of
afety at 14 days post administration of the first dose.
.2. Construction of S. typhi (Ty2 aroC− ssaV− ssaG−
ltB) TSB7 (ETEC Vaccine 1)
The construction of the vaccine strain in ETEC Vaccine
, S. typhi (Ty2 aroC− ssaV− ssaG− eltB) TSB7 has been
escribed previously [7]. Briefly, the ssaG− eltB fusion was
ntroduced into the chromosome of S. typhi ZH9 (Ty2 aroC
ssaV) at the site of the attenuating aroC deletion by trans-
ormation with the suicide vector construct pCVD442/ssaG−
ltB. One strain, termed S. typhi TSB7 (Ty2 aroC ssaV
saG− eltB), was selected for further study. The insertion of
he ssaG− eltB into the aroC deletion of S. typhi ZH9 (Ty2
aroC ssaV) and the integrity of the ssaV deletion were
onfirmed by PCR, Southern blot and sequence analysis.
.3. Microbiological, hematological, biochemical, and
linical monitoring
Blood, stool, and urine cultures were collected before
mmunization on day of immunization, daily for 7 days, and
eekly for 28 days after the administration of the first and
econd dose of the vaccine. According to standard United
ingdom Public Health practice, persons infected with non-
yphoidal Salmonella should be considered non-infectious
hen two separate stool samples are negative on culture. The
rotocol stated that, if a volunteer demonstrated (beyond Day
) persistent fecal shedding of S. typhi, then oral ciprofloxacin
ould be administered, and the volunteer monitored until two
onsecutive samples were negative.
Blood, stool and urine cultures were performed by the rou-
ine pathology service of St. George’s Hospital. Fecal samples
ere inoculated onto desoxycholate citrate agar plus aro-
atic supplements (DCAaro) and a small aliquot emulsified
n selenite F plus aromatic supplements (SFaro) enrichment
roth. After overnight incubation at 37 ◦C, one loopful of
Faro broth was subcultured onto a fresh DCAaro plate to
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btain discrete colonies. Equal volumes of urine and dou-
le strength SFaro broth were incubated at 37 ◦C for 24 h. A
oopful of broth was removed and inoculated onto DCAaro
lates. Five milliliter of blood was inoculated into aerobic
nd anaerobic bottles, maintaining a blood/broth ratio of
:10 and incubated at 37 ◦C by using the Organon Teknika
acT/Alert blood culture system. Blood cultures were contin-
ously monitored for 5 days, and a gram stain was performed
n all bottles triggering a positive reaction. Those contain-
ng gram-negative bacilli were subcultured onto xylose lysine
esoxycholate agar (XLD). Non-lactose-fermenting isolates
n XLD and negative by oxidase test were characterized for
iochemical reaction by using the Analytical Profile Index
ystem (bioMe´rieux). Organisms identified as Salmonella
ere serotyped by using Salmonella agglutinating antisera
PROLAB and Central Public Health Laboratory, Colindale,
K). Urea and electrolytes, liver function tests, full blood
ount, erythrocyte sedimentation rate were measured in the
outine pathology laboratories of St. George’s Hospital. Vol-
nteers kept a daily record of symptoms for 28 days post each
ose and 7 days prior to each dose, including frequency and
onsistency of stool, headache, fever, nausea, vomiting, and
ther constitutional upset.
.4. ELISA and ELISPOT assays for S. typhi-LPS
peciﬁc serum IgG antibody and IgA ASC responses
Blood samples were collected prior to immunization
nd then on Days 7, 14, 21, 28, after each dose for
he enzyme-linked immunosorbant assay (ELISA). For the
nzyme-linked immunospot (ELISPOT) assays blood sam-
les were collected prior to immunization and then on
ays 7, 11, 14 (not for LPS), after each dose. Serum
as frozen at −70 ◦C until analysis by ELISA. Peripheral
lood mononuclear cells (PBMCs) were collected from the
olunteers and assayed for the presence of specific antibody-
ecreting cells (ASCs) by using the ELISPOT technique.
riefly, PBMCs obtained by venepuncture were isolated by
icoll–Paque centrifugation. PBMCs in concentrations of
.5 × 105, 5.0 × 105 and 1 × 106 cells in 100l of RPMI
640/Glutamax/FBS/Penicillin/Streptomycin for each sam-
le to be tested were added to wells of 96 well Multiscreen-IP
itrocellulose microtiter plates, which were either uncoated
control wells) or previously coated for 120–130 min at
7 ◦C with 5g/ml lipopolysaccharide, S. typhosa (S. typhi)
Sigma Chemical L-6386) in Reggiardo’s Buffer plus 0.1%
odium deoxycholate and unbound binding sites blocked with
BS/3% BSA. Cells were incubated overnight at 37 ◦C in
% CO2. After incubation the plates were washed and wells
eceived 100l of phosphatase-labelled goat anti-human IgA
ntibody diluted 1:1000 in phosphate buffered saline (PBS).
fter 60–70 min incubation at 37 ◦C with gentle shaking,
ells were washed, and spots were then visualized by the
ddition of NBT (nitroblue tetrazolium)-BCIP (5-brom-4-
hloro-3-indolylphosphate) and enumerated under low power
agnification. To account for non-specific binding of the
a
t
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ells to the wells of the plate, the mean number of spots
n uncoated wells was subtracted from the mean number of
pots in antigen-coated wells to give a mean number of ASCs.
he mean of the number of ASCs (adjusted for dilution fac-
or) for the three dilutions of each sample was determined
nd expressed as ASCs/106 PBMCs.
For the ELISA, the same reagents and dilutions for coating
mmunlon 4HBX plates were used as in the ELISPOT assay.
eplicate 100l aliquots of serum diluted in PBS/1% BSA
ere added to the antigen coated and uncoated wells, seri-
lly diluted across the plate. Each plate contained dilutions of
ositive control sera from volunteers vaccinated with Vivotif
Berna). After 1 h incubation at 37 ◦C plates were washed
nd 100l of rabbit anti-human IgG (DAKO A0423) was
dded to each well. Plates were incubated at 37 ◦C for 60 min,
ashed and then 100l of goat anti-rabbit IgG alkaline phos-
hatase conjugate (ISL 075-1506) added to each well and the
late incubated for a further 60 min at 37 ◦C. Anti-LPS IgG
ctivity was detected by incubating the wells for 30 min at
oom temperature with pNPP substrate and the absorbance
ead at 405 nm. The antibody titer was defined as the dilution
equired to reduce the signal for a given sample to back-
round levels, and for each timepoint the titer was compared
gainst day zero serum run simultaneously to calculate a fold
ncrease.
.5. ELISA and ELISPOT assays for heat labile toxin
LT) speciﬁc serum IgG antibody and IgA ASC responses
PBMCs were prepared from fresh blood and diluted in
he same concentrations as for the ELISPOT assay for S.
yphi-LPS ASC response described previously and added
o wells of 96 well Multiscreen-IP nitrocellulose microtiter
lates, which were either uncoated (control wells) or previ-
usly coated for 2 h at 37 ◦C with 5g/ml of purified heat
abile toxin (LT) from E. coli (Berna Biotech Custom Batch)
n carbonate coating buffer. Cells were incubated overnight
t 37 ◦C in 5% CO2. After the plates were washed, wells
eceived 100l of goat anti-human IgA-alkaline phosphatase
abelled antibody (Immune systems Ltd. 075-1001) diluted
:1000 in 1% BSA/PBS. After 1 h incubation at 37 ◦C, wells
ere washed and spots were then visualized by the addition of
BT-BCIP and enumerated under low power magnification.
he number of ASCs was calculated as described previously
nd expressed as ASCs/106 PBMCs.
Monosialoganglioside GM1 (GM1) has a high binding
ffinity for heat labile toxin (LT) and was exploited in the
ssay to detect anti-heat labile specific IgG. Hundred micro-
iters of GM1 (0.5g/ml) in Reggiardo’s buffer plus 0.1%
odium deoxycholate was added to wells of Immulon 4HBX
96 wells) microtiter plates and incubated overnight at 37 ◦C.
he unbound binding sites were blocked with PBS/3% BSA
nd after washing, 100l of LT (1.0g/ml in PBS) was added
o the designated coated wells. Plates were incubated for 1 h at
7 ◦C. After washing, replicate 100l serum samples diluted
n PBST/1% BSA were added to the coated and uncoated
4 cine 25
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shedding, between the high and low dose groups, or for first
and second immunizations. These data suggest that the shed-
ding observed represents transient passage of bacteria and
not sustained colonization.
Table 1
Number of patients reporting gastrointestinal adverse events considered
related to the vaccine by severity
Symptoms Mild Moderate Severe
108 Dose (n = 12)
All gastrointestinal disorders 9 (75) 3 (25) 1 (8)
Abdominal pain/discomfort 7 (58) 2 (17) 1 (8)
Anorexia 1 (8) 0 (0) 0 (0)
Constipation 1 (8) 1 (8) 0 (0)
Culture stool positive 0 (0) 0 (0) 0 (0)
Diarrhea 0 (0) 0 (0) 0 (0)
Flatulence 4 (33) 0 (0) 0 (0)
Nausea 1 (8) 0 (0) 0 (0)
Vomiting 0 (0) 0 (0) 0 (0)
109 Dose (n = 24)
All gastrointestinal disorders 18 (75) 2 (8) 0 (0)
Abdominal pain/discomfort 12 (50) 1 (4) 0 (0)
Anorexia 1 (4) 0 (0) 0 (0)
Constipation 6 (25) 0 (0) 0 (0)
Culture stool positive 1 (4) 0 (0) 0 (0)
Diarrhea 1 (4) 1 (4) 0 (0)
Flatulence 14 (58) 1 (4) 0 (0)
Nausea 4 (16) 0 (0) 0 (0)
Vomiting 1 (4) 0 (0) 0 (0)178 S. Khan et al. / Vac
ells, serially diluted across the plate. Each plate contained
ilutions of positive control sera from volunteers vaccinated
ith Dukoral (SBL). After 1 h incubation at 37 ◦C plates were
ashed and 100l of goat anti-human IgG (Southern Biotech
040-01) was added to each well and incubated for 1 h at
7 ◦C. After washing 100l of rabbit anti-goat IgG HRP
onjugate (ISL 14-13-06) was added to each well and the
late incubated for a further 60 min at 37 ◦C. Anti-LT IgG
ctivity was detected by incubating the wells for 10 min at
oom temperature with OPD substrate and the absorbance
ead at 405 nm. The antibody titer was defined as the dilution
equired to reduce the signal for a given sample to back-
round levels, and for each timepoint the titer was compared
gainst day zero serum run simultaneously to calculate a fold
ncrease.
.6. Deﬁnition of a positive response in ELISA and
LISPOT
For serum IgG antibody responses, Day 0 serum was
un in the ELISA for each antigen at each time point after
mmunization and 4-fold or greater increase from Day 0 in
ntigen-specific serum IgG on either Day 7,14, 21 28, or 56
as taken as a response to the first immunization; and on Days
3, 70, 77, 84 as a response to the second. For the ELISPOT
n increase above baseline in the number (to 10 or more) of
SCs per 106 PBMCs which secreted antigen-specific IgA
n day 7 or 11 or 14 after each vaccination was considered a
ositive response.
.7. Statistical analysis
Analyses were performed as the number and percentage
f subjects with an immune response concluding with a two-
ided 95% exact CI. The p-value from two-sided Fisher’s
xact Test at the 5% significance level (testing against an
ssumed immune response of 50%) was also calculated.
. Results
.1. Clinical monitoring
The ETEC Vaccine 1 was extremely well tolerated. There
ere no serious vaccine-related adverse events. All vaccine-
elated adverse events were transient and mild-moderate
everity. There was no dose–response in the frequency of
dverse events. As with other oral immunization studies
mploying bicarbonate buffer to neutralize gastric acid, mild
o moderate and transient gastrointestinal symptoms were
ommonly recorded. Only one subject recorded gastroin-
estinal cramps graded as ‘severe’ which occurred 7 days
fter ingesting the first dose of 108 CFU. Table 1 lists the fre-
uency of gastrointestinal adverse events post-immunization.
wo subjects withdrew from the study, both in the 109 CFU
roup and both before the second dose was given. One sub-
T
t
a
I(2007) 4175–4182
ect withdrew consent, and another was withdrawn from the
tudy due to epigastric pain 53 and 56 days after the first
mmunization, thought to be caused by a suspected peptic
lcer.
Ten subjects reported a fever at some time during the study
eriod, but there was no obvious pattern for the timing of fever
n relation to the dosing, except one subject who reported
fever on Day 3 after first dose of 109 CFU and this was
he only event of fever that could possibly be related to the
dministration of the vaccine. All events of fever were mild
n nature, except one event of a moderate fever on Day 10
fter the first dose of 108 CFU.
There were no vaccine-related and clinically-significant
bnormalities of hematological or biochemical parameters
uring the study.
.2. Microbiological monitoring
No subjects developed bacteraemia post-immunization.
he fecal shedding profile was consistent with that described
reviously [8], with the majority of subjects exhibiting only
ransient shedding within the first 3 days following immu-
ization (Table 2). Only one subject shed the vaccine beyond
ay 6, with isolated fecal shedding on Day 14. The frequency
nd pattern of fecal shedding is shown in Table 2. There were
o obvious differences in the duration or time of onset of stoolotal of subjects recording any event, subjects may record events of more
han one severity grade. Figures in parentheses indicate percentage of group
t that dose level (12 subjects in 108 CFU, and 24 subjects in 109 CFU group).
n the 109 CFU group, two subjects did not receive a second immunization.
S. Khan et al. / Vaccine 25
Table 2
Fecal shedding of vaccine strain after immunization
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tD: vaccine growth on direct plating without requirement for enrichment; E:
vaccine growth after enrichment only; –: no growth; *: sample not available.
Grayed-out rows indicate subject did not receive second dose.
.3. Immune responses
Table 3 shows the immune responses detected by
LISPOT or ELISA separately for subjects completing the
rotocol, at the different dose levels and for each individual
ntigen.
For the responses to S. typhi lipopolysaccharide: The vac-
ine induced frequent and high level responses to S. typhi
ipopolysaccharide, as described previously in trials [9] of
he parent strain S. typhi ZH9 which lacks the ssaG− eltB
usion. Taking all 36 subjects recruited on as an intention-to-
reat population, 97% demonstrated an IgG or IgA immune
esponse against S. typhi lipopolysaccharide measured either
y ELISPOT or ELISA, and the majority of responders had
oth an IgG response (89%), as measured by ELISA, and an
gA response (92%), as measured by ELISPOT. When the
bserved response rates to S. typhi lipopolysaccharide were
ested against an assumed response rate of 50%, for all tests,
s
t
(
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he p-values for the proportions of responders were <0.05,
howing that the responses observed could be confidently
eclared to be different to the assumed response of 50%.
hus, the insertion of the ssaG− eltB fusion did not effect
he ability of ETEC Vaccine 1 to induce high level responses
gainst S. typhi lipopolysaccharide.
For the responses to ETEC LT: Amongst the 36 subjects
ecruited, 67% demonstrated an IgG or IgA immune response
gainst ETEC LT measured either by ELISPOT or ELISA.
o dose–response was apparent with the same percentage of
ubjects in each dose group developing an immune response
108 CFU: 8/12, 67%; 109 CFU: 16/24, 67%). The majority
f the responders in each group had an IgG response (22 sub-
ects overall, 61%), as measured by ELISA, but few subjects
4 subjects overall, 11%) had an IgA response, as measured by
LISPOT. For both vaccine groups, and for all subjects com-
ined, the observed response rates to LT were tested against
n assumed response rate of 50%. However, for all tests, the
-values for the proportions of responders were not statisti-
ally significant, showing that the responses observed could
ot be confidently declared to be different to the assumed
esponse of 50%. However, in the UK population it would be
xtremely unlikely for a subject to seroconvert to ETEC LT,
s this organism is not present in the environment, and so a
0% seroconversion rate is probably too strict.
For subjects receiving 108 CFU: After first immunization
ean peak IgG titer to LT 2625 (peak fold increase 2.5), mean
eak IgA ASC response to LT 0, mean peak IgG titer to LPS
073 (15.4), mean peak IgA ASC response to LPS 121. After
econd immunization mean peak IgG titer to LT 4743 (peak
old increase 3.7), mean peak IgA ASC response to LT 0.9,
ean peak IgG titer to LPS 3672 (16.5) mean peak IgA ASC
esponse to LPS 15.7.
For subjects receiving 109 CFU: After first immunization
ean peak IgG titer to LT 4184 (peak fold increase 4.2), mean
eak IgA ASC response to LT 8.29, mean peak IgG titer to
PS 3724 (13.1), mean peak IgA ASC response to LPS 158.
fter second immunization mean peak IgG titer to LT 3056
peak fold increase 3.5), mean peak IgA ASC response to LT
.73, mean peak IgG titer to LPS 1680 (7.9), mean peak IgA
SC response to LPS 13.
Given the small number of subjects studied at each dose
evel, and the wide scatter in the responses, interpretation of
he correlation between responses measured in the two assays
o the two antigens must be interpreted with caution. Non-
arametric Spearman correlation with two-tailed p-values,
as employed using GraphPad Prism as a preliminary inves-
igation of the effect of the carrier response on the response
o the heterologous antigen.
A positive correlation was observed between the peak
erum IgG response to S. typhi LPS after the first immuniza-
ion and the peak serum IgG response to S. typhi LPS after the
econd immunization, and the peak ASC IgA responses to S.
yphi LPS after the first but not the second immunization
Spearman correlation coefficients: 0.89, 0.62, −0.06; p-
alues: <0.0001, <0.0001, 0.75, respectively). There was also
4180 S. Khan et al. / Vaccine 25 (2007) 4175–4182
Table 3
Frequency of LT-B and LPS responses
n First immunization n Second immunization First or Second Immunization
Number of positive responders to S. typhi LPS
108 CFU
ELISA 1212 10 (83) 12 9 (75) 10 (83)
ASCs 11 (92) 12 4 (33) 11 (92)
109 CFU
ELISA 24 19 (79) 22 16 (73) 22 (92)
ASCs 24 21 (86) 22 8 (36) 22 (92)
Number of positive responders to LT-B
108 CFU
ELISA 12 5 (42) 12 5 (42) 7 (58)
ASCs 12 0 12 1 (8) 1 (8)
109 CFU
ELISA 24 10 (42) 22 10 (45) 15 (63)
ASCs 24 3 (13) 22 0 3 (13)
Number of subjects with a positive response at any time point after each immunization as defined for each assay (percentage of group in parentheses—note
in the 109 group two subjects did not receive a second immunization). For ELISA positive response defined as ≥4-fold increase in serum IgG antibody titer
b d as ≥1
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tetween each time point and Day 0. For ELISPOT positive response define
ach immunization.
positive correlation between the peak serum IgG response
o S. typhi LPS after the first immunization and the peak ASC
gA responses to ETEC LT after the first but not the second
mmunization (Spearman correlation coefficients: 0.43, 0.27;
-values: 0.009, 0.12, respectively). There was no correlation
n the peak serum IgG response to S. typhi LPS after the sec-
nd immunization and the peak ASC response to LPS after
he second immunization (Spearman correlation coefficient:
.06; p = 0.71). As there was a correlation between the serum
gG responses to first and second immunizations, these obser-
ations raise the possibility that the ASC responses to LPS
ay have followed a different time course after the second
mmunization, resulting in the peak response being missed,
ather than immunity from the first immunization blocking a
esponse to the second.
A positive correlation was observed between the peak
erum IgG response to ETEC LT after the first immunization
nd the peak serum IgG response to ETEC LT after the sec-
nd immunization, and with the peak ASC IgA responses to
TEC LT after the first and second immunizations (Spearman
orrelation coefficients: 0.89, 0.60, 0.59; p values: <0.0001,
0.0001, 0.0002, respectively). There was also a positive
orrelation between the peak serum IgG response to ETEC
T after the second immunization and the peak ASC IgA
esponses to ETEC LT after the first and second immuniza-
ions (Spearman correlation coefficients: 0.52, 0.55; p values:
.002, 0.0006, respectively). There was no correlation in the
eak serum IgG response to ETEC LT after the first or sec-
nd immunizations and any of the responses to S. typhi LPS.
hese data suggest that the response to LPS did not affect theesponse to ETEC LT, and that the first immunization tended
o prime for the second immunization to ETEC LT both in
egard to serum and IgA ASCs. There also appears to have
een less effect of the first immunization on the timing ASC
e
i
r0 ASCs/106 PBMC secreting antigen-specific IgA at Day 7, 11 or 14 after
esponse to the second, possibly indicating a less powerful
riming for LT compared with LPS.
. Discussion
With an estimated 210 million cases of ETEC-induced
iarrhea and 380,000 deaths worldwide each year [10],
vaccine that will prevent or ameliorate the severity of
TEC infection in humans is urgently required. The major
athogenic mechanisms of ETEC include colonization of the
mall intestine and elaboration of one or more enterotoxins
hat through various mechanisms may induce water and elec-
rolyte secretion resulting in diarrhea [11,12]. As part of the
olonization process, ETEC possess specialized pili that act
s ligands to bind the bacterial cells to specific complex car-
ohydrate receptors on the epithelial cell surfaces of the small
ntestine. Since this interaction results in colonization of the
ntestine by ETEC, with subsequent multiplication on the
ut surface, these pili are termed colonization-factor antigens
CFA). Numerous CFA have been identified and there is con-
iderable diversity in the expression of these across different
linical isolates [13–15]. These CFA enable ETEC to over-
ome the peristaltic defense mechanism of the small intestine
n order to colonize the bowel. Following colonization,
TEC–enterotoxins stimulate excessive electrolyte and fluid
ecretion, primarily from the small intestine crypt cells, by
nducing increased formation of cyclic adenosine monophos-
hate (AMP) and/cyclic guanosine monophosphate (GMP) in
he epithelial cells [10,16].ETEC may produce either or both of a heat labile
nterotoxin (LT) and a heat stable enterotoxin (ST). LT
s structurally, functionally and immunologically closely
elated, although not identical, to cholera toxin (CT). LT con-
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ists of five copies of the B subunit and one copy of the A
ubunit and both these proteins cross-react immunologically
ith the corresponding CT subunit proteins. The anti-LT
mmune response is mainly directed against the B-subunit
ortion of the molecule [10,16]. The demonstration that an
ral vaccine consisting of whole cell killed cholera plus CT-B
1,2] can provide protective immunity against ETEC pro-
ides a strong rationale for the development a subunit vaccine
gainst ETEC based on LT. The oral whole cell/CT-B vaccine
as further evaluated in Finnish travelers going to Morocco,
nd found to confer 60–70% protection [17]. Based on these
ata the whole cell cholera vaccine has been licensed in
weden and Norway as an ETEC vaccine (Dukoral®).
As wild-type ETEC strains express a large variety of col-
nization factors, a vaccine based on the conserved LT-B
olecule is attractive. Therefore, the findings reported above
ave stimulated considerable interest in the potential for
eveloping LT-B as a travelers’ vaccine. Antibodies to LT
re also protective against ETEC in animals [18]. There are
everal vaccines against travelers’ diarrhea caused by ETEC
n development. One of the most promising approaches is
he use of live attenuated vaccines given by the oral route,
ither based on attenuation of the ETEC strains directly, or
sing a live attenuated vector such as Salmonella to deliver
TEC antigens. Live attenuated organisms can be developed
o be highly effective vaccines; immune responses elicited
an often be of greater magnitude and of longer duration
han those produced by non-living antigens [19,20].
Because of their intimate interaction with the gut asso-
iated lymphoid tissue (GALT), live attenuated Salmonella
ake attractive vectors for the delivery of heterologous anti-
ens from other pathogens. They can also be given orally
nd live Salmonellae are known to stimulate potent humoral,
ellular and secretory anti-Salmonella responses against co-
xpressed heterologous antigens [21], including LT-B in
nimal models [3–7]. We have previously tested a live atten-
ated S. typhi-based oral typhoid vaccine in humans, named
. typhi (Ty2 aroC− ssaV−) ZH9 [8]. This strain was sub-
equently used as a vector to express LT-B, which resulted
n potent anti-LT responses in mice following intranasal and
ubcutaneous administration [7,22]. This S. typhi vector har-
ors independently attenuating deletion mutations in thearoC
nd ssaV genes. The aroC gene encodes chorismate synthase,
n enzyme involved in the biosynthesis of aromatic com-
ounds [23,24]. The ssaV gene encodes a component of the
ype III secretion system encoded on Salmonella pathogenic-
ty island 2 (SPI-2) [25]. In addition, a SPI-2-associated in
ivo inducible ssaG promoter was used to drive the expres-
ion of LT-B [24]. Also, in order to enhance the stability of
he construct in vivo the promoter/antigen fusion was inserted
nto the S. typhi chromosome [7,26].
In this study, we found that ETEC Vaccine 1 was able to
eliably induce both serum IgG and mucosal IgA responses
o S. typhi lipopolysaccharide in over 95% of subjects at both
he low and high dose levels—a crucial characteristic of a
rotective vaccine against typhoid, and in keeping with our
a
o
o(2007) 4175–4182 4181
revious experience of the parent strain. This also indicates
hat the insertion of the LT gene has not compromised the
tness of the organism in its ability to establish a vaccine
ake and induce both systemic and mucosal immunity, a major
ttraction of orally delivered live attenuated vaccines.
Generally, live attenuated Salmonella have been some-
hat disappointing in their ability to induce immune
esponses to heterologous antigens after oral delivery to
umans, in contrast to their immunogenicity in murine mod-
ls. In addition there may be a discordance between mucosal
gA responses detected by ELISPOT and serum IgG antibody.
or example, while oral administration of CVD 909 (a live
ttenuated S. typhi strain engineered to constitutively express
he S. typhi capsular antigen Vi), induced detectable levels of
i specific IgA antibody-secreting cells, in the majority of
uman volunteers only 2/32 recipients generated serum anti-
i IgG antibody [27]. Furthermore, while a prototype live
ttenuated S. typhi vaccine engineered to express the urease
ntigen of Helicobacter pylori [28,29], induced T cell prim-
ng in around 56% of volunteers receiving one or more dose
rally, no serological responses to the heterologous antigen
ould be detected. Therefore, our observation that 67% of
ll volunteers demonstrated an IgG or IgA immune response
gainst ETEC LT measured either by ELISPOT or ELISA,
ndependent of dose level, is the first demonstration in a
uman trial to our knowledge that a recombinant S. typhi can
ffectively prime for a humoral response to a heterologous
ntigen in humans. The fact that only a single, integrated copy
f the LT gene is present in the strain, rather than multicopy
lasmid expression, makes the immune responses observed
ven more significant and demonstrates the utility of the ssaG
romoter in driving immunologically relevant levels of anti-
en. The lack of a carrier effect, whereby immunity to the
arrier inhibits immune responses, as demonstrated in this
tudy by responses to both first and second immunizations is
lso encouraging.
Our observation that ETEC Vaccine 1 was well toler-
ted, relatively unreactogenic, did not cause vaccinemia, and
nduced only transient low level shedding in volunteers is
rucial for further clinical development. In particular, the
ow level of stool shedding is an important consideration,
s release into the environment is a key feature of genetically
odified organism identified by regulatory authorities. Fur-
hermore, the lack of enhanced shedding or reactogenicity
y the insertion of the LT-B protein is significant, as theoret-
cally the presence of LT-B on the surface of the organism
ould enhance gut binding to GM1 gangliosides area. The
ack of appreciable side effects combined with the induction
f anti-LT specific immune responses in the majority of vac-
ines support the further development of ETEC Vaccine 1 as
n effective ETEC vaccine. Furthermore, the broad applica-
ility of the spi-VEC strain should allow the development of
multivalent live attenuated enteropathogen vaccines based
n this technology.
In conclusion, this pilot human study has shown that a 108
r 109 dose of live attenuated S. typhi expressing ETEC LT
4 cine 25
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ntigen is well tolerated, and highly immunogenic, induc-
ng humoral immune responses to the inserted antigen in
round two-thirds of subjects immunized orally after one or
wo doses.
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